Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Renal Cell 63Carcinoma, Hepatocellular 25Prostatic Neoplasms 21Neoplasm Metastasis 19Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Carcinoma, Transitional Cell 9Sarcoma 8Colorectal Neoplasms 8Carcinoma, Medullary 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3

Interventions

Zoledronic Acid 4Denosumab 3Vitamin D 2saracatinib 1radium Ra 223 dichloride 1odanacatib 1etelcalcetide hydrochloride 1cabozantinib 1Standard of Care 1Progestins 1Pamidronate 1Paclitaxel 1Hormone Replacement Therapy 1Exercise 1Estrogens 1Estrogen Replacement Therapy 1Dietary Supplements 1Diet, Fat-Restricted 1Calcium 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bone Diseases × cabozantinib × Clear all
NCT01582295 2017-05-25

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Massachusetts General Hospital

Phase 1 Completed
4 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡